加载中
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
NASDAQHealthcareBiotechnology
最新数据
US$6.6785
−US$0.1015 · -1.50%
前收盘价
US$6.6785
−US$0.1015 · -1.50%
盘后
US$6.73
+US$0.0515 · +0.77%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
日内区间
当前US$6.6785
52周区间
当前US$6.6785
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
60
合理估值
情绪
51
多空交织
风险
66
高风险
动量
18
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precision T cell therapeutic engineered to address critical unmet needs in patients with acute-risk COVID-19, alongside a specific population experiencing long COVID. The company's operations are headquartered in Warren, New Jersey.
日内区间
当前US$6.6785
52周区间
当前US$6.6785
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | 40.36万 USD | 37.84万 USD | — | — |
| 毛利 | — | −40.36万 USD | −37.84万 USD | — | — |
| 研究与开发 | 1111.16万 USD | 3103.33万 USD | 440.35万 USD | — | 295.59万 USD |
| 销售、一般及管理费用 | 1502.89万 USD | 2212.76万 USD | 406.11万 USD | 95.31万 USD | 166.26万 USD |
| 营业费用 | 2614.05万 USD | 5316.09万 USD | 846.47万 USD | 95.31万 USD | 461.85万 USD |
| 利息收入 | — | — | — | 494.82万 USD | — |
| 利息支出 | 19.56万 USD | 18.4万 USD | 25.6万 USD | — | 59.85万 USD |
| 折旧和摊销 | 50.92万 USD | 40.36万 USD | 37.84万 USD | 23.08万 USD | 9377 USD |
| 营业利润 | −2614.05万 USD | −5356.45万 USD | −884.3万 USD | −95.31万 USD | −461.85万 USD |
| 净利润 | −2627.54万 USD | −1011.44万 USD | −6047.77万 USD | 440.84万 USD | −1559.68万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年3月6日 | 1:50 | — | — |
已生效 2026年3月6日
1:50
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
